权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nanoaerosols from Wick Electrospray for Improved Drug Delivery to Infants

来自灯芯电喷雾的纳米气溶胶可改善婴儿的药物输送

基本信息

批准号：
8520366
负责人：
P. Worth Longest
金额：
$ 20.62万
依托单位：
VIRGINIA COMMONWEALTH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-08-05 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8520366
关键词：
Adult Adverse effects Aerosol Drug Therapy Aerosols Alveolar Anti-Infective Agents Antibiotics Biological Availability Blood capillaries Breathing Caliber Charge Clinical Clinical Research Deposition Devices Diuretics Dose Drug Delivery Systems Electrostatics Ensure Exhalation Fostering Generations Glucocorticoids In Vitro Infant Liquid substance Lung Measurable Mechanical ventilation Medical Medicine Microprocessor Monobactams Motion Needles Neonatal Outcome Output Ozone Particle Size Patients Performance Pharmaceutical Preparations Pharmacologic Substance Polymers Power Sources Production Prostaglandins Pump Reporting Site Source Syringes System Techniques Time Tracheobronchial Tube aerosolized base capillary cost drug efficacy endotracheal improved nanometer nanoscale neonate novel particle research study respiratory simulation surfactant uptake

项目摘要

DESCRIPTION (provided by applicant): The delivery of aerosolized medications to neonates and infants on mechanical ventilation is expected to provide a number of benefits including increased drug concentrations at the site of action within the airways, improved drug efficacy, and reduced side effects. Presently, clinical outcomes of aerosol therapy delivered to infants for a variety of medical conditions are often disappointing or inconclusive. Current aerosol generation techniques for use with neonates and infants on mechanical ventilation have been shown to deliver approximately 1% or less of the initial dose to the lungs. It is believed that aerosolized medicines delivered to infants are often ineffective because of low delivery efficiencies and high dose variability. The objective of this study is to develop a new wick-based electrospray system (WES) for highly efficient delivery of electrostatically charged submicrometer and nanometer scale aerosols to the respiratory airways of neonates and infants during invasive mechanical ventilation. In contrast with previous devices for aerosol delivery, the WES system is intended to generate aerosols in the submicrometer (< 1000 nm) and nanometer (< 100 nm) size regimes. The small size of the aerosol droplets will dramatically reduce deposition in the delivery lines and allow a large fraction of the dose to enter the airways. Once inside the lungs, the inherent charge of the electrospray droplets as well as Brownian motion of the nanometer aerosol will foster enhanced deposition and ensure almost complete lung retention. Compared with conventional electrospray, the WES device replaces the syringe pump and capillary with a porous polymer wick, which reduces device cost and complexity. Furthermore, the corona needle of typical electrospray devices is removed, which eliminates the formation of ozone. In order to develop this novel device for respiratory drug delivery, the following specific aims are proposed. Specific Aim 1: Develop a polymer-based wick electrospray (WES) system for generating and delivering charged submicrometer and nanometer pharmaceutical aerosols. Specific Aim 2: Optimize the performance of the WES system in terms of increasing the aerosol output rate and minimizing deposition within the device and delivery lines. Specific Aim 3: Evaluate the transport and deposition of WES aerosols in the respiratory airways of infants using in vitro experiments and CFD simulations. The proposed device will provide, for the first time, a source of submicrometer droplets with minimal device and delivery line deposition (< 20-30%) and full lung retention of the aerosol, which represents a 1 to 2 order of magnitude improvement compared with current devices. Potential applications where improved delivery efficiency to the lungs, reduced dose variability, and deposition within the entire airways of infants are of critical importance include the use of aerosolized surfactants, antibiotics, prostanoids, and diuretics.

描述（由申请人提供）：将雾化药物输送给机械通气的新生儿和婴儿有望提供许多益处，包括增加气道内作用部位的药物浓度、提高药物疗效和减少副作用。目前，对各种疾病的婴儿进行气雾剂治疗的临床结果往往令人失望或不确定。目前用于新生儿和机械通气婴儿的气溶胶生成技术已被证明可向肺部输送约1%或更少的初始剂量。据认为，由于给药效率低和剂量变化大，给婴儿的雾化药物往往无效。本研究的目的是开发一种新的基于磁芯的电喷雾系统（WES），用于在有创机械通气期间向新生儿和婴儿呼吸道高效输送静电带电的亚微米和纳米级气溶胶。与以前的气溶胶输送装置相比